47O - Phase 1 Study of Bispecific HER2 Antibody-Drug Conjugate MEDI4276 in Patients with Advanced HER2-Positive Breast or Gastric Cancer

Date 05 March 2018
Event TAT 2018 - Targeted Anticancer Therapies
Session Proffered Paper Session 1
Topics Cytotoxic agents
Gastric Cancer
Breast Cancer
Presenter Mark Pegram
Citation Annals of Oncology (2018) 29 (suppl_3): iii7-iii9. 10.1093/annonc/mdy048
Authors M. Pegram1, E. Hamilton2, A.R. Tan3, A.M. Storniolo4, N. Elgeioushi5, S. Marshall5, S. Abdullah5, M. Patel6
  • 1Department Of Medicine, Stanford Comprehensive Cancer Institute, CA 94305-545 - Stanford/US
  • 2Florida Cancer Specialists/Sarah Cannon Research Institute, Nashville/US
  • 3Levine Cancer Institute, Charlotte/US
  • 4Indiana University Simon Cancer Center, Indianapolis/US
  • 5MedImmune, Gaithersburg/US
  • 6Florida Cancer Specialists, Sarasota/US


MEDI4276 is a HER2-bispecific antibody targeting two different epitopes on HER2, with site-specific conjugation via maleimidocaproyl linker to a potent tubulysin-based microtubule inhibitor. MEDI4276 demonstrates enhanced cellular internalization and cytolysis of HER2+ tumor cells in vitro, including T-DM1 resistant cells.